Latest news with #ShareIntel
Associated Press
15-04-2025
- Business
- Associated Press
Sonim Technologies Announces Engagement with Shareholder Intelligence Services, LLC to Protect Shareholders and Maximize Value
San Diego, California--(Newsfile Corp. - April 15, 2025) - Sonim Technologies, Inc. (NASDAQ: SONM), a leading provider of rugged mobile solutions, today announced it has engaged Shareholder Intelligence Services, LLC ('ShareIntel') as part of its ongoing commitment to safeguarding shareholders and driving shareholder value. Through ShareIntel's patented and proprietary service offerings, Sonim will gain access to advanced share trading analytics designed to enhance corporate governance, strengthen shareholder communication, support regulatory compliance, and monitor trading in the Company's securities. Clay Crolius, CFO of Sonim Technologies, commented, 'We are pleased to announce our collaboration with ShareIntel as we take another step forward in protecting our shareholders and reinforcing transparency. This partnership will empower us to better monitor trading activity, including identifying potential anomalies or violations of SEC regulations. We believe this will enhance confidence in our stock and underscore our dedication to delivering value to all our stakeholders.' David Wenger, President & CEO of ShareIntel, added, 'We are proud to support Sonim Technologies in their commitment to shareholder protection and corporate oversight. Our compliance-driven SaaS platform monitors trading and settlement activity with the goal of ensuring that true stock supply-and-demand dynamics enable accurate price discovery for public companies.' About Shareholder Intelligence Services, LLC ShareIntel is a compliance driven SAAS retained by public companies to obtain, aggregate, track and analyze shareholder trading and settlement data. This patented process is managed through its 'Data Repository Information Link' system DRIL-Down™. The ShareIntel solution empowers public company CEO's, CFO's, IRO's, Corporate Secretaries & General Council with tools and analysis to help better manage investment banking, investor relations, shareholder outreach efforts and more. ShareIntel provides actionable intelligence, which enables public company officers and directors to fulfill fiduciary best practices. About Sonim Technologies Sonim Technologies is a leading U.S. provider of rugged mobile solutions, including phones, wireless internet data devices, accessories and software designed to provide extra protection for users that demand more durability in their work and everyday lives. Trusted by first responders, government, and Fortune 500 customers since 1999, we currently sell our ruggedized mobility solutions through tier one wireless carriers and distributors in North America, EMEA, and Australia/New Zealand. Sonim devices and accessories connect users with voice, data, workflow and lifestyle applications that enhance the user experience while providing an extra level of protection. For more information, visit Media Contact Anette Gaven [email protected] 1-619-993-3058 Important Cautions Regarding Forward-Looking Statements This release contains forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995, as amended. These statements relate to, among other things, the projected revenue growth, the declaring and reaffirming of Sonim's business strategy and objectives, the successful expansion of Sonim's products in new markets, and Sonim's ability to grow and to capitalize the market opportunity. These forward-looking statements are based on Sonim's current expectations, estimates and projections about its business and industry, management's beliefs and certain assumptions made by Sonim, all of which are subject to change. Forward-looking statements generally can be identified by the use of forward-looking terminology such as 'achieve,' 'aim,' 'ambitions,' 'anticipate,' 'believe,' 'committed,' 'continue,' 'could,' 'designed,' 'estimate,' 'expect,' 'forecast,' 'future,' 'goals,' 'grow,' 'guidance,' 'intend,' 'likely,' 'may,' 'milestone,' 'objective,' 'on track,' 'opportunity,' 'outlook,' 'pending,' 'plan,' 'position,' 'possible,' 'potential,' 'predict,' 'progress,' 'promises,' 'roadmap,' 'seek,' 'should,' 'strive,' 'targets,' 'to be,' 'upcoming,' 'will,' 'would,' and variations of such words and similar expressions or the negative of those terms or expressions. Such statements involve risks and uncertainties, which could cause actual results to vary materially from those expressed in or indicated by the forward-looking statements. Factors that may cause actual results to differ materially include, but are not limited to, the following: the availability of cash on hand; potential material delays in realizing projected timelines; the current interest and potential attempt of hostile takeover from a third party may divert the management attention from Sonim's business and may require significant expenses; Sonim's material dependence on its relationship with a small number of customers who account for a significant portion of Sonim's revenue; Sonim's entry into the data device sector could divert our management team's attention from existing products; risks related to Sonim's ability to comply with the continued listing standards of the Nasdaq Stock Market and the potential delisting of Sonim's common stock; Sonim's ability to continue to develop solutions to address user needs effectively, including its next-generation products; Sonim's reliance on third-party contract manufacturers and partners; Sonim's ability to stay ahead of the competition; Sonim's ongoing transformation of its business; the variation of Sonim's quarterly results; the lengthy customization and certification processes for Sonim's wireless carries customers; various economic, political, environmental, social, and market events beyond Sonim's control, as well as the other risk factors described under 'Risk Factors' included in Sonim's most recent Annual Report on Form 10-K and any subsequent quarterly filings on Form 10-Q filed with the Securities and Exchange Commission (available at ). Sonim cautions you not to place undue reliance on forward-looking statements, which speak only as of the date hereof. Sonim assumes no obligation to update any forward-looking statements in order to reflect events or circumstances that may arise after the date of this release, except as required by law. To view the source version of this press release, please visit
Yahoo
15-04-2025
- Business
- Yahoo
Sonim Technologies Announces Engagement with Shareholder Intelligence Services, LLC to Protect Shareholders and Maximize Value
San Diego, California--(Newsfile Corp. - April 15, 2025) - Sonim Technologies, Inc. (NASDAQ: SONM), a leading provider of rugged mobile solutions, today announced it has engaged Shareholder Intelligence Services, LLC ("ShareIntel") as part of its ongoing commitment to safeguarding shareholders and driving shareholder value. Through ShareIntel's patented and proprietary service offerings, Sonim will gain access to advanced share trading analytics designed to enhance corporate governance, strengthen shareholder communication, support regulatory compliance, and monitor trading in the Company's securities. Clay Crolius, CFO of Sonim Technologies, commented, "We are pleased to announce our collaboration with ShareIntel as we take another step forward in protecting our shareholders and reinforcing transparency. This partnership will empower us to better monitor trading activity, including identifying potential anomalies or violations of SEC regulations. We believe this will enhance confidence in our stock and underscore our dedication to delivering value to all our stakeholders." David Wenger, President & CEO of ShareIntel, added, "We are proud to support Sonim Technologies in their commitment to shareholder protection and corporate oversight. Our compliance-driven SaaS platform monitors trading and settlement activity with the goal of ensuring that true stock supply-and-demand dynamics enable accurate price discovery for public companies." About Shareholder Intelligence Services, LLC ShareIntel is a compliance driven SAAS retained by public companies to obtain, aggregate, track and analyze shareholder trading and settlement data. This patented process is managed through its "Data Repository Information Link" system DRIL-Down™. The ShareIntel solution empowers public company CEO's, CFO's, IRO's, Corporate Secretaries & General Council with tools and analysis to help better manage investment banking, investor relations, shareholder outreach efforts and more. ShareIntel provides actionable intelligence, which enables public company officers and directors to fulfill fiduciary best practices. About Sonim TechnologiesSonim Technologies is a leading U.S. provider of rugged mobile solutions, including phones, wireless internet data devices, accessories and software designed to provide extra protection for users that demand more durability in their work and everyday lives. Trusted by first responders, government, and Fortune 500 customers since 1999, we currently sell our ruggedized mobility solutions through tier one wireless carriers and distributors in North America, EMEA, and Australia/New Zealand. Sonim devices and accessories connect users with voice, data, workflow and lifestyle applications that enhance the user experience while providing an extra level of protection. For more information, visit Media ContactAnette Gavenpr@ Important Cautions Regarding Forward-Looking Statements This release contains forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995, as amended. These statements relate to, among other things, the projected revenue growth, the declaring and reaffirming of Sonim's business strategy and objectives, the successful expansion of Sonim's products in new markets, and Sonim's ability to grow and to capitalize the market opportunity. These forward-looking statements are based on Sonim's current expectations, estimates and projections about its business and industry, management's beliefs and certain assumptions made by Sonim, all of which are subject to change. Forward-looking statements generally can be identified by the use of forward-looking terminology such as "achieve," "aim," "ambitions," "anticipate," "believe," "committed," "continue," "could," "designed," "estimate," "expect," "forecast," "future," "goals," "grow," "guidance," "intend," "likely," "may," "milestone," "objective," "on track," "opportunity," "outlook," "pending," "plan," "position," "possible," "potential," "predict," "progress," "promises," "roadmap," "seek," "should," "strive," "targets," "to be," "upcoming," "will," "would," and variations of such words and similar expressions or the negative of those terms or expressions. Such statements involve risks and uncertainties, which could cause actual results to vary materially from those expressed in or indicated by the forward-looking statements. Factors that may cause actual results to differ materially include, but are not limited to, the following: the availability of cash on hand; potential material delays in realizing projected timelines; the current interest and potential attempt of hostile takeover from a third party may divert the management attention from Sonim's business and may require significant expenses; Sonim's material dependence on its relationship with a small number of customers who account for a significant portion of Sonim's revenue; Sonim's entry into the data device sector could divert our management team's attention from existing products; risks related to Sonim's ability to comply with the continued listing standards of the Nasdaq Stock Market and the potential delisting of Sonim's common stock; Sonim's ability to continue to develop solutions to address user needs effectively, including its next-generation products; Sonim's reliance on third-party contract manufacturers and partners; Sonim's ability to stay ahead of the competition; Sonim's ongoing transformation of its business; the variation of Sonim's quarterly results; the lengthy customization and certification processes for Sonim's wireless carries customers; various economic, political, environmental, social, and market events beyond Sonim's control, as well as the other risk factors described under "Risk Factors" included in Sonim's most recent Annual Report on Form 10-K and any subsequent quarterly filings on Form 10-Q filed with the Securities and Exchange Commission (available at Sonim cautions you not to place undue reliance on forward-looking statements, which speak only as of the date hereof. Sonim assumes no obligation to update any forward-looking statements in order to reflect events or circumstances that may arise after the date of this release, except as required by law. To view the source version of this press release, please visit Sign in to access your portfolio
Yahoo
24-03-2025
- Business
- Yahoo
Allarity Therapeutics Launches Comprehensive Effort to Combat Potential Illegal Naked Short Selling of Its Shares
Boston (March 24, 2025)—Allarity Therapeutics, Inc. ('Allarity' or the 'Company') (NASDAQ: ALLR), a Phase 2 clinical-stage pharmaceutical company dedicated to developing stenoparib—a differentiated dual PARP/Wnt pathway inhibitor—today announced that it has engaged Shareholder Intelligence Services, LLC ('ShareIntel') to investigate potential illegal naked short selling and other potential trading irregularities by third parties in the Company's common stock. The engagement with ShareIntel is part of Allarity's commitment to protecting shareholder value and ensuring fair and transparent trading of its stock. ShareIntel utilizes its proprietary DRIL-Down™ technology, a compliance-driven data analytics platform, to track and analyze stock trading activity from broker-dealers, clearing firms, and reporting entities. Through this agreement, Allarity will monitor potential trading abuses, detect unusual short-selling patterns, and investigate possible market manipulation, taking corrective action, including legal recourse if necessary. Thomas Jensen, CEO of Allarity Therapeutics, commented: 'We have engaged ShareIntel as part of our commitment to protecting shareholder value and fostering confidence in the market for our stock. As we continue advancing the clinical development of stenoparib, ensuring trust that our shares are traded fairly and free from manipulation remains a key priority. In response to investor inquiries and our observations of notable stock volatility on multiple occasions, we believe this collaboration with ShareIntel is both timely and appropriate.'The Company will leverage ShareIntel's market surveillance tools to detect potential violations of the U.S. Securities and Exchange Commission's Regulation SHO, which governs short-selling practices, stock borrowing requirements, and fail-to-deliver obligations. If evidence of market manipulation or illegal short selling is uncovered, Allarity will consider all available options to hold responsible parties accountable. About StenoparibStenoparib is an orally available, small-molecule dual-targeted inhibitor of PARP1/2 and tankyrase 1/2. At present, tankyrases are attracting significant attention as emerging therapeutic targets for cancer, principally due to their role in regulating the Wnt signaling pathway. Aberrant Wnt/β-catenin signaling has been implicated in the development and progression of numerous cancers. By inhibiting PARP and blocking Wnt pathway activation, stenoparib's unique therapeutic action shows potential as a promising therapeutic for many cancer types, including ovarian cancer. Allarity has secured exclusive global rights for the development and commercialization of stenoparib, which was originally developed by Eisai Co. Ltd. and was formerly known under the names E7449 and 2X-121. About Allarity TherapeuticsAllarity Therapeutics, Inc. (NASDAQ: ALLR) is a clinical-stage biopharmaceutical company dedicated to developing personalized cancer treatments. The Company is focused on development of stenoparib, a novel PARP/tankyrase inhibitor for advanced ovarian cancer patients, using its DRP® technology to develop a companion diagnostic that can be used to select those patients expected to derive the greatest clinical benefit from stenoparib. Allarity is headquartered in the U.S., with a research facility in Denmark, and is committed to addressing significant unmet medical needs in cancer treatment. For more information, visit Follow Allarity on Social MediaLinkedIn: Forward-Looking Statements This press release contains 'forward-looking statements' within the meaning of the Private Securities Litigation Reform Act of 1995. Forward-looking statements provide the Company's current expectations or forecasts of future events. The words 'anticipates,' 'believe,' 'continue,' 'could,' 'estimate,' 'expect,' 'intends,' 'may,' 'might,' 'plan,' 'possible,' 'potential,' 'predicts,' 'project,' 'should,' 'would' and similar expressions may identify forward-looking statements, but the absence of these words does not mean that a statement is not forward-looking. These forward-looking statements include, but are not limited to, expectations regarding the investigation into potential naked short selling and trading irregularities, the findings from ShareIntel's analysis, and the Company's ability to take appropriate corrective action. Any forward-looking statements in this press release are based on management's current expectations of future events and are subject to multiple risks and uncertainties that could cause actual results to differ materially and adversely from those set forth in or implied by such forward-looking statements. These risks and uncertainties include, but are not limited to the effectiveness of ShareIntel's investigation, the identification of any trading irregularities, the potential impact of corrective measures, and the Company's ability to protect shareholder value. For a discussion of other risks and uncertainties, and other important factors, any of which could cause our actual results to differ from those contained in the forward-looking statements, see the section entitled 'Risk Factors' in our Form S-1/A registration statement filed on April 17, 2024, our Form 10-K annual report on file with the Securities and Exchange Commission (the 'SEC') and our Form 10-Q quarterly report filed with the SEC on November 14, 2024, available at the SEC's website at and as well as discussions of potential risks, uncertainties and other important factors in the Company's subsequent filings with the SEC. All information in this press release is as of the date of the release, and the Company undertakes no duty to update this information unless required by law. ### Company Contact: investorrelations@ Media Contact: Thomas Pedersen Carrotize PR & Communications +45 6062 9390 tsp@ Attachment Allarity Therapeutics Press Release - Comprehensive Effort to Combat Potential Illegal Naked Short SellingSign in to access your portfolio
Associated Press
24-03-2025
- Business
- Associated Press
Allarity Therapeutics Launches Comprehensive Effort to Combat Potential Illegal Naked Short Selling of Its Shares
Boston (March 24, 2025)—Allarity Therapeutics, Inc. ('Allarity' or the 'Company') (NASDAQ: ALLR), a Phase 2 clinical-stage pharmaceutical company dedicated to developing stenoparib—a differentiated dual PARP/Wnt pathway inhibitor—today announced that it has engaged Shareholder Intelligence Services, LLC ('ShareIntel') to investigate potential illegal naked short selling and other potential trading irregularities by third parties in the Company's common stock. The engagement with ShareIntel is part of Allarity's commitment to protecting shareholder value and ensuring fair and transparent trading of its stock. ShareIntel utilizes its proprietary DRIL-Down™ technology, a compliance-driven data analytics platform, to track and analyze stock trading activity from broker-dealers, clearing firms, and reporting entities. Through this agreement, Allarity will monitor potential trading abuses, detect unusual short-selling patterns, and investigate possible market manipulation, taking corrective action, including legal recourse if necessary. Thomas Jensen, CEO of Allarity Therapeutics, commented: 'We have engaged ShareIntel as part of our commitment to protecting shareholder value and fostering confidence in the market for our stock. As we continue advancing the clinical development of stenoparib, ensuring trust that our shares are traded fairly and free from manipulation remains a key priority. In response to investor inquiries and our observations of notable stock volatility on multiple occasions, we believe this collaboration with ShareIntel is both timely and appropriate.' The Company will leverage ShareIntel's market surveillance tools to detect potential violations of the U.S. Securities and Exchange Commission's Regulation SHO, which governs short-selling practices, stock borrowing requirements, and fail-to-deliver obligations. If evidence of market manipulation or illegal short selling is uncovered, Allarity will consider all available options to hold responsible parties accountable. About Stenoparib Stenoparib is an orally available, small-molecule dual-targeted inhibitor of PARP1/2 and tankyrase 1/2. At present, tankyrases are attracting significant attention as emerging therapeutic targets for cancer, principally due to their role in regulating the Wnt signaling pathway. Aberrant Wnt/β-catenin signaling has been implicated in the development and progression of numerous cancers. By inhibiting PARP and blocking Wnt pathway activation, stenoparib's unique therapeutic action shows potential as a promising therapeutic for many cancer types, including ovarian cancer. Allarity has secured exclusive global rights for the development and commercialization of stenoparib, which was originally developed by Eisai Co. Ltd. and was formerly known under the names E7449 and 2X-121. About Allarity Therapeutics Allarity Therapeutics, Inc. (NASDAQ: ALLR) is a clinical-stage biopharmaceutical company dedicated to developing personalized cancer treatments. The Company is focused on development of stenoparib, a novel PARP/tankyrase inhibitor for advanced ovarian cancer patients, using its DRP® technology to develop a companion diagnostic that can be used to select those patients expected to derive the greatest clinical benefit from stenoparib. Allarity is headquartered in the U.S., with a research facility in Denmark, and is committed to addressing significant unmet medical needs in cancer treatment. For more information, visit Follow Allarity on Social Media LinkedIn: X: Forward-Looking Statements This press release contains 'forward-looking statements' within the meaning of the Private Securities Litigation Reform Act of 1995. Forward-looking statements provide the Company's current expectations or forecasts of future events. The words 'anticipates,' 'believe,' 'continue,' 'could,' 'estimate,' 'expect,' 'intends,' 'may,' 'might,' 'plan,' 'possible,' 'potential,' 'predicts,' 'project,' 'should,' 'would' and similar expressions may identify forward-looking statements, but the absence of these words does not mean that a statement is not forward-looking. These forward-looking statements include, but are not limited to, expectations regarding the investigation into potential naked short selling and trading irregularities, the findings from ShareIntel's analysis, and the Company's ability to take appropriate corrective action. Any forward-looking statements in this press release are based on management's current expectations of future events and are subject to multiple risks and uncertainties that could cause actual results to differ materially and adversely from those set forth in or implied by such forward-looking statements. These risks and uncertainties include, but are not limited to the effectiveness of ShareIntel's investigation, the identification of any trading irregularities, the potential impact of corrective measures, and the Company's ability to protect shareholder value. For a discussion of other risks and uncertainties, and other important factors, any of which could cause our actual results to differ from those contained in the forward-looking statements, see the section entitled 'Risk Factors' in our Form S-1/A registration statement filed on April 17, 2024, our Form 10-K annual report on file with the Securities and Exchange Commission (the 'SEC') and our Form 10-Q quarterly report filed with the SEC on November 14, 2024, available at the SEC's website at and as well as discussions of potential risks, uncertainties and other important factors in the Company's subsequent filings with the SEC. All information in this press release is as of the date of the release, and the Company undertakes no duty to update this information unless required by law. Company Contact: Media Contact: Thomas Pedersen Carrotize PR & Communications
